Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients

Addiction Biology

Volumn 14, Issue 2, 2009, Pages 227-237

  Ebner, Nina ^a   Wanner, Christian ^a   Winklbaur, Bernadette ^a   Matzenauer, Christian ^a   Jachmann, Crispa Aeschbach ^a   Thau, Kenneth ^a   Fischer, Gabriele ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Depressive symptoms; Hepatitis C; Interferon; Maintenance treatment; Opioid dependent patients; Ribavirin

Indexed keywords

BUPRENORPHINE; HEMOGLOBIN; HEPATITIS C ANTIBODY; METHADONE; MORPHINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANOREXIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD CHANGE; MULTICENTER STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SIDE EFFECT; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TRANSMISSION; WEAKNESS;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHRONIC DISEASE; FEMALE; GENOTYPE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RETENTION (PSYCHOLOGY); RIBAVIRIN; YOUNG ADULT;

EID: 61849098815     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2009.00148.x     Document Type: Article

References (42)

1. American Psychiatric Association (APA) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC : American Psychiatric Association.
2. Asnis GM, De La Garza R (2006) Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 40 : 322 335.
3. Bauer SM, Loipl R, Jagsch R, Gruber D, Risser D, Thau K, Fischer G (2008) Mortality in opioid-maintained patients after release from an addiction clinic. Eur Addict Res 14 : 82 91.
4. Beck AT, Steer RA (1994) Beck Depressions-Inventar (BDI) Testhandbuch. Hautzinger M, Bailer M, Worrall H, Keller F (Hrsg. D. dt. Ausg); Bern; Göttingen Toronto : Verlag Hans Huber.
5. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, Negro F (2005) Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 42 : 323 328.
6. Centers for Disease Control and Prevention (1998) Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 47 (RR-19 1 39.
7. Ebner N, Rohrmeister K, Winklbaur B, Baewert A, Jagsch R, Peternell A, Thau K, Fischer G (2007) Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 87 : 131 138.
8. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B (2001) Is it justified to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 345 : 221 214.
9. Emit® (1983) Assay Troubleshooting Guide. Palo Alto, CA : Syva Co.
10. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136 : 288 292.
11. Ferenci P, Brunner H, Laferl H, Th S, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K (2008) A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with Peginterferon alfa-2a in HCV Genotypes and 3. Hepatology 47 : 1816 1823.
12. Ferenci P, Staufer K (2008) Depression in chronic hepatitis: the virus, the drug or the ethnic background? Liver Int 28 : 429 431.
13. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H (2006) Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 101 : 275 281.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, FLJr G, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 26 347 : 975 982.
15. Gombas W, Fischer G, Jagsch R, Eder H, Okamoto I, Schindler S, Müller C, Ferenci P, Kasper S (2000) Prevalence and distribution of hepatitis C subtypes in patients with opioid dependence. Eur Addict Res 6 : 198 204.
16. Gsellhofer B, Küfner H, Vogt M, Weiler D (1999) European Addiction Severity Index - EuropASI. Baltmannweiler : Schneider Verlag Hohengehren.
17. Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, Carioti M, Monarca R, Antinori A (2007) Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 102 : 423 431.
18. Hallinan R, Byrne A, Amin J, Dore GJ (2005) Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 20 : 1082 1086.
19. Hallinan R, Byrne A, Agho K, Dore GJ (2007) Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 88 : 49 53.
20. Huber M, Weber R, Opplinger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner EL (2005) Interferon alpha-2a plus ribavirin 1000/1200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis c infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 33 : 25 29.
21. Loftis JM, Matthews AM, Hauser P (2006) Psychiatric and substance use disorders in individuals with hepatits C. Drugs 66 : 155 174.
22. Lorvick J, Kral AH, Seal KH, Gee L, Edlin BR (2001) Prevalence and duration of hepatitis C among injection drug users in San Francisco, California. Am J Public Health 91 : 46 47.
23. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG (2009) Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 65 : 344 348.
24. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New Engl J Med 339 : 1485 1492.
25. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 : 958 965.
26. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G (2004) A prospective controlled study of interferon-based therapy of chronic hepatitis. Hepatology 40 : 120 124.
27. National Institutes of Health (NIH) (2002) Consensus development conference statement. Management of hepatitis C. Hepatology 36 : 3 20.
28. Neri S, Pulvirenti D, Bertino G (2006) Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha2a and interferon-alpha-2b. Clin Drug Investig 26 : 655 662.
29. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 : 1426 1432.
30. Reece AS (2009) Chronic viral hepatitis is a significant contributor to the immunosenescent phenotype of parenteral drug addiction. Addict Biol, Feb 4 [Epub ahead of print] PMID: 18811680.
31. Robaeys G, Buntinx F (2005) Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 68 : 55 67.
32. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L (2002) Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 129 : 577 585.
33. Schaefer M, Heinz A, Backmund M (2004) Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 99 : 1167 1175.
34. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K (2003) Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37 : 443 450.
35. Shehab TM, Orrego M, Chunduri R, Lok ASF (2003) Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 98 : 639 644.
36. Stoove MA, Gifford SM, Dore GJ (2005) The impact of injecting drug use status on hepatitis C related referral and treatment. Drug Alcohol Depend 77 : 81 86.
37. Strauss SM, Astone J, Vassilev ZP, Des Jarlais DC, Hagan H (2003) Gaps in the drug-free and methadone treatment program response to hepatitis C. J Subst Abuse Treat 24 : 291 297.
38. Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S (2005) Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 77 : 214 224.
39. Sylvestre DL (2002) Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 67 : 117 123.
40. Sylvestre DL (2005) Treating hepatitis C virus infection in active substance users. Clin Infect Dis 40 : 321 324.
41. Sylvestre DL, Clements BJ (2007) Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 19 : 741 747.
42. Van Zerssen D (1976) Die Beschwerdeliste Manual. Klinische Selbstbeurteilungsskalen (KSb-S) aus dem Münchner Psychiatrischen Informationssystem. Weinheim : Beltz.